Visiox Pharma has entered into a definitive agreement with Santen Pharmaceutical to license product manufacturing and commercialization rights for Omlonti in the U.S., according to a press release.
Santen will receive an equity stake in Visiox upfront and will be eligible to receive sales milestone payments and royalties on net sales of Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% in the U.S.
The prostaglandin E2 receptor agonist was approved by the FDA in 2022 to reduce elevated IOP in the treatment of open-angle glaucoma or ocular hypertension.
Visiox plans to launch Omlonti in